Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tagraxofusp, Venetoclax, and Chemotherapy in BPDCN
NCT04216524Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- May 2020
- Primary completion
- Dec 2026
- Modality
- Immunotoxins, Small Molecules, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tagraxofusp and venetoclax in Blastic plasmacytoid dendritic cell neoplasm (BPDCN), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Progression-Free Survival up to 6 years, Incidence of adverse events up to 6 years and 2 more. Started May 2020; status: recruiting.
02
Drugs
tagraxofuspvenetoclax
03
Conditions
Blastic plasmacytoid dendritic cell neoplasm (BPDCN)
Beyond the preview
Go deeper on NCT04216524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04216524.